<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394042</url>
  </required_header>
  <id_info>
    <org_study_id>Proxiscan</org_study_id>
    <nct_id>NCT01394042</nct_id>
  </id_info>
  <brief_title>Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint</brief_title>
  <official_title>Exploratory Evaluation of a Transrectal Scintigraphic Detector (Proxiscan) for Detection of Primary Prostate Cancer Utilizing a Radiotracer Targeting Prostate Specific Membrane Antigen (PMSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiological Associates of Sacramento Medical Group Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hybridyne Imaging Technologies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiological Associates of Sacramento Medical Group Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a small study to determine if probe, similar to an ultrasound probe, can detect
      prostate cancer more specifically than other imaging studies in patients with a positive
      prostate cancer biopsy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of PSMA antibody (ProstaScint)uptake patterns measured by Proxiscan in comparison with anatomic biopsy reports, conventional SPECT and MRI scans within one month of Proxiscan</measure>
    <time_frame>Within on month of scan and corresponding MRI</time_frame>
    <description>Detection of PSMA antibody (ProstaScint) uptake patterns measured by the new transrectal compact gamma camera (Proxiscan) will be compared to the anatomic biopsy reports along with Magnetic Resonance Imaging (MRI) and conventional ProstaScint (Single Photon Emission Computed Tomography) SPECT imaging results. All imaging and biopsy results performed within one month will be used for this investigation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All consenting patients will be imaged with the Proxiscan and data compared with MRI, ProstaScint and biopsy data</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Proxiscan device</intervention_name>
    <description>All patients will be imaged with the device</description>
    <arm_group_label>No intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary prostate cancer proven by sextant prostate biopsy

          -  Transrectal ultrasound (TRUS)-guided prostate biopsy within 6 months of study
             enrollment

          -  Sufficient time period to complete imaging protocol and 5-7 day safety followup
             assessment without other therapeutic intervention

          -  In the judgement of principal investigator, patient able to provide informed consent
             and be compliant with protocol requirements

          -  ECOG status of 0 or 1 Pt &gt; 18 yrs of age

        Exclusion Criteria:

          -  Definitive or concomitant therapeutic intervention within the interval of study
             intervention

          -  Prior pelvic therapeutic radiation

          -  Active malignancy or therapy for malignancy with 6 months other than basal or squamous
             cell carcinoma of the skin

          -  Pt received radiopharmaceutical which was within 5 half-lives at the time of studying
             imaging

          -  Known history of human-anti-murine-antibodies or known allergic reaction to previously
             received murine based products
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Franc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiological Associates of Sacramento Medical Group Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roseville PET and Nuclear Imaging Center</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2011</study_first_posted>
  <last_update_submitted>July 12, 2011</last_update_submitted>
  <last_update_submitted_qc>July 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Benjamin Franc, MD/PI</name_title>
    <organization>RAS</organization>
  </responsible_party>
  <keyword>Biopsy proven primary prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

